Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Assets: 2023-2024

Historic Current Assets for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $206.4 million.

  • Contineum Therapeutics' Current Assets fell 14.04% to $184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.9 million, marking a year-over-year decrease of 14.04%. This contributed to the annual value of $206.4 million for FY2024, which is 61.61% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Current Assets of $206.4 million as of FY2024, which was up 61.61% from $127.7 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Current Assets ranged from a high of $206.4 million in FY2024 and a low of $127.7 million during FY2023.
  • Moreover, its 2-year median value for Current Assets was $167.0 million (2023), whereas its average is $167.0 million.
  • Data for Contineum Therapeutics' Current Assets shows a peak YoY surged of 61.61% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Current Assets (Yearly) stood at $127.7 million in 2023, then spiked by 61.61% to $206.4 million in 2024.